Whole blood RNA sequencing of African American kidney transplant recipients from VericiDx cohort
The VericiDx cohort is an ongoing clinical trial (241 patients (32.0% self-reported AA) enrolled as of 06/30/2023) with a focus on predicting early acute rejection and renal fibrosis post-transplantation (ClinicalTrials.gov: NCT04727788). Overall design: Pretransplant RNA sequencing profiles (101 PE reads) were generated on pretransplant blood, with a subset of 77 recipients. The RNA data in these 77 AA recipients was combined with two cohorts to identify the meta-gene signatures associated with the LILRB3-4SNPs. The LILRB3-4SNPs was correlated with early eGFR values (within two years) in meta-analysis with other three cohorts. However, the relatively short follow-up duration for many patients in this cohort limited the association analysis for graft failure.